Text size: AAA
Step into summer in the best shape of your life with these reports from Harvard Medical School.
Learn How

Start your exercise and fitness program and reap the benefits of being more fit, stronger and healthier!

Warmer weather is on the way and it's not too late to get in shape for the summer. These 3 reports can help you enjoy outdoor activities in the best shape of your life:

References for "Antidepressants and tamoxifen"

JUN 2010

Next Article:

Did you know?

You can get instant online access to all of the articles from the June 2010 issue of Harvard Mental Health Letter for only $5.

Already a subscriber? Login for complete instant access.

If you want a button/link to remove the box (not sure if you do or not...), it would look like this: Cancel

Andersohn F, et al. “Interaction of Serotonin Reuptake Inhibitors with Tamoxifen,” BMJ (Feb. 2010): Vol. 340, electronic publication. www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=20142323

Borges S, et al. “Quantitative Effect of CYP2D6 Genotype and Inhibitors on Tamoxifen Metabolism: Implication for Optimization of Breast Cancer Treatment,” Clinical and Pharmacological Therapies (July 2006): Vol. 80, No. 1, pp. 61–74. www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=16815318

Chubak J, et al. “Breast Cancer Recurrence Risk in Relation to Antidepressant Use After Diagnosis,” Breast Cancer Research and Treatment (Nov. 2008): Vol. 112, No. 1, pp. 123–32. www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=18058227

Desmarais JE, et al. “Interactions Between Tamoxifen and Antidepressants via Cytochrome P450 2D6,” Journal of Clinical Psychiatry (Dec. 2009): Vol. 70, No. 12, pp. 1688–97. www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=20141708

Early Breast Cancer Trialists’ Collaborative Group. “Effects of Chemotherapy and Hormonal Therapy for Early Breast Cancer on Recurrence and 15-Year Survival: An Overview of the Randomised Trials,” Lancet (May 14–20, 2005): Vol. 365, No. 9472, pp. 1687–717.

Goetz MP, et al. “The Impact of Cytochrome P450 2D6 Metabolism in Women Receiving Adjuvant Tamoxifen,” Breast Cancer Research and Treatment (Jan. 2007): Vol. 101, No. 1, pp. 113–21. www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=17115111

Jin Y, et al. “CYP2D6 Genotype, Antidepressant Use, and Tamoxifen Metabolism During Adjuvant Breast Cancer Treatment,” Journal of the National Cancer Institute (Jan. 5, 2005): Vol. 97, No. 1, pp. 30–39. www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=15632378

Kelly CM, et al. “Selective Serotonin Reuptake Inhibitors and Breast Cancer Mortality in Women Receiving Tamoxifen: A Population Based Cohort Study,” BMJ (Feb. 2010): Vol. 340, electronic publication. www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=20142325

Lash TL, et al. “Tamoxifen's Protection Against Breast Cancer Recurrence is Not Reduced by Concurrent Use of the SSRI Citalopram,” British Journal of Cancer (Aug. 19, 2008): Vol. 99, No. 4, pp. 616–21. www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=18665165

Lehmann D, et al. “Lack of Attenuation in the Antitumor Effect of Tamoxifen by Chronic CYP Isoform Inhibition,” Journal of Clinical Pharmacology (Aug. 2004): Vol. 44, No. 8, pp. 861–65. www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=15286089

Stearns V, et al. “Active Tamoxifen Metabolite Plasma Concentrations After Coadministration of Tamoxifen and the Selective Serotonin Reuptake Inhibitor Paroxetine,” Journal of the National Cancer Institute (Dec. 3, 2003): Vol. 95, No. 23, pp. 1758–64. www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=14652237

Next Article: